JNJ Looks 37.8% Overvalued on GF Value™ as Dividend Sustainabili
Johnson & Johnson (JNJ) announced that its experimental treatment JNJ-5120/PIPE-307 failed to meet the primary endpoint in a phase 2 trial for major depressive disorder. The company's dividend yield is 1.95% with a payout ratio of 50% and a 3-year growth rate of 4.9%. JNJ's stock is trading 37.8% above its intrinsic GF Value™ of $193.33, with a GF Score™ of 83/100. Insiders have sold $154.9 million in shares over the past year.
How this was made
The 30-second read
Why it matters
The failed trial adds a new risk factor to JNJ's pipeline, potentially affecting its valuation and investor sentiment.
Market read
The news is material for investors focused on pharma pipelines and dividend income, prompting possible short‑term price adjustments.
What to watch
Strong dividend yield and robust cash flow could support the stock despite the trial setback.
Background
Johnson & Johnson is a diversified healthcare giant with a focus on pharmaceuticals, medical devices, and a strong dividend track record.
Ticker impact
Johnson & Johnson announced its experimental treatment JNJ-5120/PIPE-307 failed the primary endpoint in the MOONLIGHT-1 phase 2 trial for major depressive disorder.
downward pressure on the stock in the short term
Phase 2 failures often lead to re‑rating of the company's growth prospects and can trigger sell‑offs, especially for a large‑cap like JNJ.
Market effects
May dampen sentiment for the broader neurology/psychiatric drug development sector.
Limited to U.S. healthcare equities, with potential spillover to global pharma stocks.
Modest; primarily affects large‑cap pharma investors.
Counterpoint
If the company can pivot the compound to another indication, the long‑term impact may be limited.
Key entities
- CompanyJohnson & Johnson
US‑listed healthcare conglomerate (NYSE: JNJ).
- DrugJNJ-5120/PIPE-307
Experimental treatment for major depressive disorder.
